CA
NZ
UK
AU
IND
US
Nektar Therapeutics (NASDAQ: NKTR) is trading at $63.89 pre-market June 22, up 4.77% from the June 18 close of $60.98. Nektar is a clinical-stage biopharmaceutical company focused on immunological dysfunction in autoimmune, chronic inflammatory diseases, and oncology, with lead asset rezpegaldesleukin (REZPEG/NKTR-358), a first-in-class …
Oruka Therapeutics, Inc. (NASDAQ: ORKA) is trading at $78.45 pre-market June 22, up 8.45% from the June 18 close of $72.34. Oruka is a clinical-stage biotechnology company developing best-in-class monoclonal antibody therapeutics for chronic skin diseases including plaque psoriasis, psoriatic arthritis, and hidradenitis suppurativa, …
MoonLake Immunotherapeutics (NASDAQ: MLTX) is trading at $23.05 pre-market June 22, up 20.01% from the June 18 close of $19.21. MoonLake is a clinical-stage biopharmaceutical company developing sonelokimab, a tri-specific IL-17A and IL-17F inhibiting Nanobody for inflammatory skin and joint diseases including hidradenitis suppurativa, …
Merck & Co., Inc. (NYSE: MRK) is trading at $113.18 pre-market June 22, down 0.61% from the June 18 close of $113.87. Merck is an American multinational pharmaceutical company offering a broad portfolio spanning oncology, vaccines, infectious diseases, cardiovascular conditions, immunology, and veterinary medicine, …
Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) is trading at $17.58 pre-market June 22, up 6.79% from the June 18 close of $16.46. Aurinia is a commercial-stage biopharmaceutical company developing and commercialising innovative therapies for autoimmune diseases, with flagship product LUPKYNIS (voclosporin) as the first FDA-approved …
Apogee Therapeutics, Inc. (NASDAQ: APGE) is trading at $139.34 pre-market June 22, up 54.17% from the June 18 close of $90.38. Apogee is a clinical-stage biotechnology company developing differentiated biologics for atopic dermatitis, COPD, asthma, eosinophilic esophagitis, and other inflammatory and immunology indications using …
Eli Lilly and Company (NYSE: LLY) is trading at $1,103.00 pre-market June 22, up 0.44% from the June 18 close of $1,098.57. Lilly is a leading American multinational pharmaceutical company developing innovative medicines spanning cardiometabolic health, oncology, immunology, and neuroscience, with blockbuster GLP-1 treatments …
Immunovant, Inc. (NASDAQ: IMVT) is trading at $37.89 pre-market June 22, up 7.22% from the June 18 close of $35.34. Immunovant is a clinical-stage immunology company developing innovative anti-FcRn monoclonal antibody therapies to enable normal lives for patients with autoimmune diseases, with lead candidates …
Relmada Therapeutics (NASDAQ: RLMD) occupies an increasingly active niche at the intersection of CNS pharmacology and oncology, where mechanistic research is revealing overlapping pathways between neurological processes and cancer biology that can be exploited through drug repurposing and indication expansion strategies.
Hims and Hers Health (NYSE: HIMS) has been executing a deliberate portfolio diversification strategy that extends the platform beyond its original men's health focus into women's health, weight management, and mental health, each of which addresses large and underserved patient populations with strong willingness-to-pay …
Please wait processing your request...